Non-invasive fibrosis markers are useful in predicting the presence of varices in compensated cirrhosis and variceal bleeding in decompensated cirrhosis.
cirrhosis
non-invasive fibrosis markers
varice prediction
variceal bleeding
Journal
Internal and emergency medicine
ISSN: 1970-9366
Titre abrégé: Intern Emerg Med
Pays: Italy
ID NLM: 101263418
Informations de publication
Date de publication:
10 Oct 2024
10 Oct 2024
Historique:
received:
30
06
2024
accepted:
30
09
2024
medline:
10
10
2024
pubmed:
10
10
2024
entrez:
9
10
2024
Statut:
aheadofprint
Résumé
This study aims to investigate the effectiveness of non-invasive fibrosis markers in predicting varices in compensated advanced chronic liver disease patients and variceal bleeding in decompensated cirrhotic patients. Between 1 July 2020-2021, 137 newly diagnosed cirrhosis patients (67 females/70 males; mean age: 53.35) were included in the study. The diagnosis of cirrhosis was made based on clinical, laboratory, imaging, and, if available, biopsy findings. Laboratory and clinical parameters, including lysyl oxidase-like protein 2 (LOXL2), were recorded for all patients. Commonly used noninvasive fibrosis scores were calculated, and endoscopies were performed to assess varices. All patients were followed up for 12 months, and variceal bleeding events were recorded. Parameters that could predict the presence of varices and variceal bleeding were identified using appropriate statistical methods. Out of the 137 cirrhotic patients, 55 were in the compensated stage and 82 were in the decompensated stage. Varices were detected in 36 (65%) of the compensated cirrhotic patients. It was found that a variceal score derived from spleen size and the ELF score could be used to predict varices (AUC: 0.83). Variceal bleeding developed in 26 (31%) of the patients with decompensated cirrhosis. It was determined that a scoring system derived from albumin, spleen size, LOXL2 level, and the Lok index could be used to predict variceal bleeding in this patient group (AUC: 0.845). This study demonstrates that, besides device-dependent examinations, non-invasive fibrosis scores and various serum parameters can predict varices and variceal bleeding in cirrhotic patients.
Identifiants
pubmed: 39384666
doi: 10.1007/s11739-024-03788-0
pii: 10.1007/s11739-024-03788-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Società Italiana di Medicina Interna (SIMI).
Références
Jensen DM (2002) Endoscopic screening for varices in cirrhosis: findings, implications, and outcomes. Gastroenterology 122(6):1620–1630. https://doi.org/10.1053/gast.2002.33419
doi: 10.1053/gast.2002.33419
de Franchis R, Baveno VIF (2015) Expanding consensus in portal hypertension: report of the baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol 63(3):743–752. https://doi.org/10.1016/j.jhep.2015.05.022
doi: 10.1016/j.jhep.2015.05.022
Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J (2017) Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology 65(1):310–335. https://doi.org/10.1002/hep.28906
doi: 10.1002/hep.28906
Jakab SS, Garcia-Tsao G (2019) Screening and Surveillance of Varices in Patients With Cirrhosis. Clin Gastroenterol Hepatol 17(1):26–29. https://doi.org/10.1016/j.cgh.2019.02.025
doi: 10.1016/j.cgh.2019.02.025
de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Baveno VIIF (2022) Baveno VII—Renewing consensus in portal hypertension. J Hepatol 76(4):959–974. https://doi.org/10.1016/j.jhep.2021.12.022
doi: 10.1016/j.jhep.2021.12.022
Lichtinghagen R, Pietsch D, Bantel H, Manns MP, Brand K, Bahr MJ (2013) The enhanced liver fibrosis (ELF) score: normal values, influence factors and proposed cut-off values. J Hepatol 59(2):236–242. https://doi.org/10.1016/j.jhep.2013.03.016
doi: 10.1016/j.jhep.2013.03.016
Loaeza-del-Castillo A, Paz-Pineda F, Oviedo-Cárdenas E, Sánchez-Avila F, Vargas-Vorácková F (2008) AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis. Ann Hepatol Oct-Dec 7(4):350–357. https://doi.org/10.1016/S1665-2681(19)31836-8
doi: 10.1016/S1665-2681(19)31836-8
Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, Fontaine H, Pol S (2007) FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 46(1):32–36. https://doi.org/10.1002/hep.21669
doi: 10.1002/hep.21669
Forns X, Ampurdanès S, Llovet JM, Aponte J, Quintó L, Martínez-Bauer E, Bruguera M, Sánchez-Tapias JM, Rodés J (2002) Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 36(4 Pt 1):986–992. https://doi.org/10.1053/jhep.2002.36128
doi: 10.1053/jhep.2002.36128
Giannini EG, Zaman A, Kreil A, Floreani A, Dulbecco P, Testa E, Sohaey R, Verhey P, Peck-Radosavljevic M, Mansi C, Savarino V, Testa R (2006) Platelet count/spleen diameter ratio for the noninvasive diagnosis of esophageal varices: results of a multicenter, prospective, validation study. Am J Gastroenterol 101(11):2511–2519. https://doi.org/10.1111/j.1572-0241.2006.00874.x
doi: 10.1111/j.1572-0241.2006.00874.x
Afzal Tarar B, Nadeem A, Zain Anees M, Mumtaz H, Gardezi M, Bai S (2023) Assessing the predictive efficacy of lok score in identifying esophageal varices in liver cirrhosis patients: a Cross-Sectional Study. Cureus 15(11):e48360. https://doi.org/10.7759/cureus.48360
doi: 10.7759/cureus.48360
pmcid: 10699156
Cross TJ, Rizzi P, Berry PA, Bruce M, Portmann B, Harrison PM (2009) King’s score: an accurate marker of cirrhosis in chronic hepatitis C. Eur J Gastroenterol Hepatol 21(7):730–738. https://doi.org/10.1097/MEG.0b013e32830dfcb3
doi: 10.1097/MEG.0b013e32830dfcb3
Hsieh YY, Tung SY, Lee K, Wu CS, Wei KL, Shen CH, Chang TS, Lin YH (2012) Routine blood tests to predict liver fibrosis in chronic hepatitis C. World J Gastroenterol 18(8):746–753. https://doi.org/10.3748/wjg.v18.i8.746
doi: 10.3748/wjg.v18.i8.746
pmcid: 3286137
Mortality GBD, Causes of Death C (2015) Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385(9963):117–171. https://doi.org/10.1016/S0140-6736(14)61682-2
doi: 10.1016/S0140-6736(14)61682-2
North Italian Endoscopic Club for the S, Treatment of Esophageal V (1988) Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. N Engl J Med 319(15):983–989. https://doi.org/10.1056/NEJM198810133191505
doi: 10.1056/NEJM198810133191505
Damico G, De Franchis R, Cooperative Study G (2003) Upper digestive bleeding in cirrhosis post-therapeutic outcome and prognostic indicators. Hepatology 38(3):599–612. https://doi.org/10.1053/jhep.2003.50385
doi: 10.1053/jhep.2003.50385
Taylor RS, Taylor RJ, Bayliss S, Hagstrom H, Nasr P, Schattenberg JM et al (2020) Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Gastroenterology 158(6):1611–25 e12. https://doi.org/10.1053/j.gastro.2020.01.043
doi: 10.1053/j.gastro.2020.01.043
European Association for the Study of the Liver (2021) Clinical Practice Guideline P, Chair, representative EGB, Panel m. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis—2021 update. J Hepatol 75(3):659–689. https://doi.org/10.1016/j.jhep.2021.05.025
doi: 10.1016/j.jhep.2021.05.025
Maurice JB, Brodkin E, Arnold F, Navaratnam A, Paine H, Khawar S et al (2016) Validation of the Baveno VI criteria to identify low risk cirrhotic patients not requiring endoscopic surveillance for varices. J Hepatol 65(5):899–905. https://doi.org/10.1016/j.jhep.2016.06.021
doi: 10.1016/j.jhep.2016.06.021
Silva MJ, Bernardes C, Pinto J, Loureiro R, Duarte P, Mendes M et al (2017) Baveno VI recommendation on avoidance of screening endoscopy in cirrhotic patients: are we there yet? GE Port J Gastroenterol 24(2):79–83. https://doi.org/10.1159/000452693
doi: 10.1159/000452693
Colecchia A, Ravaioli F, Marasco G, Colli A, Dajti E, Di Biase AR et al (2018) A combined model based on spleen stiffness measurement and Baveno VI criteria to rule out high-risk varices in advanced chronic liver disease. J Hepatol 69(2):308–317. https://doi.org/10.1016/j.jhep.2018.04.023
doi: 10.1016/j.jhep.2018.04.023
Augustin S, Pons M, Maurice JB, Bureau C, Stefanescu H, Ney M et al (2017) Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease. Hepatology 66(6):1980–1988. https://doi.org/10.1002/hep.29363
doi: 10.1002/hep.29363
Hu X, Huang X, Hou J, Ding L, Su C, Meng F (2021) Diagnostic accuracy of spleen stiffness to evaluate portal hypertension and esophageal varices in chronic liver disease: a systematic review and meta-analysis. Eur Radiol 31(4):2392–2404. https://doi.org/10.1007/s00330-020-07223-8
doi: 10.1007/s00330-020-07223-8
Gebregziabiher HT, Hailu W, Abay Z, Bizuneh S, Meshesha MD (2023) Accuracy of non-invasive diagnosis of esophageal varices among cirrhotic patients in a low-income setting. Heliyon 9(12):e23229. https://doi.org/10.1016/j.heliyon.2023.e23229
doi: 10.1016/j.heliyon.2023.e23229
pmcid: 10750066
Fagan KJ, Pretorius CJ, Horsfall LU, Irvine KM, Wilgen U, Choi K et al (2015) ELF score >/=9.8 indicates advanced hepatic fibrosis and is influenced by age, steatosis and histological activity. Liver Int 35(6):1673–1681. https://doi.org/10.1111/liv.12760
doi: 10.1111/liv.12760
Irvine KM, Wockner LF, Shanker M, Fagan KJ, Horsfall LU, Fletcher LM et al (2016) The Enhanced liver fibrosis score is associated with clinical outcomes and disease progression in patients with chronic liver disease. Liver Int 36(3):370–377. https://doi.org/10.1111/liv.12896
doi: 10.1111/liv.12896
Mayo MJ, Parkes J, Adams-Huet B, Combes B, Mills AS, Markin RS et al (2008) Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology 48(5):1549–1557. https://doi.org/10.1002/hep.22517
doi: 10.1002/hep.22517
Kothari HG, Gupta SJ, Gaikwad NR, Sankalecha TH, Samarth AR (2019) Role of non-invasive markers in prediction of esophageal varices and variceal bleeding in patients of alcoholic liver cirrhosis from central India. Turk J Gastroenterol 30(12):1036–1043. https://doi.org/10.5152/tjg.2019.18334
doi: 10.5152/tjg.2019.18334
pmcid: 6924602
Klepfish M, Gross T, Vugman M, Afratis NA, Havusha-Laufer S, Brazowski E et al (2020) LOXL2 inhibition paves the way for macrophage-mediated collagen degradation in liver fibrosis. Front Immunol 11:480. https://doi.org/10.3389/fimmu.2020.00480
doi: 10.3389/fimmu.2020.00480
pmcid: 7136575
Liu SB, Ikenaga N, Peng ZW, Sverdlov DY, Greenstein A, Smith V et al (2016) Lysyl oxidase activity contributes to collagen stabilization during liver fibrosis progression and limits spontaneous fibrosis reversal in mice. FASEB J 30(4):1599–1609. https://doi.org/10.1096/fj.14-268425
doi: 10.1096/fj.14-268425
Albillos A, Krag A (2023) Beta-blockers in the era of precision medicine in patients with cirrhosis. J Hepatol 78(4):866–872. https://doi.org/10.1016/j.jhep.2022.12.005
doi: 10.1016/j.jhep.2022.12.005